PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2014-03-27
Target enrollment:
Participant gender:
Summary
To evaluate the combination of PF-04856884 (CVX-060) in combination with Axitinib (AG-013736)
in patients that have received one prior systemic regimen for metastatic renal cell carcinoma
(mRCC) vs. axitinib alone.